Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Goodwill & Intangibles (2024 - 2025)

ARS Pharmaceuticals' Goodwill & Intangibles history spans 2 years, with the latest figure at $13.0 million for Q2 2025.

  • For Q2 2025, Goodwill & Intangibles changed N/A year-over-year to $13.0 million; the TTM value through Jun 2025 reached $13.0 million, changed N/A, while the annual FY2024 figure was $7.4 million, N/A changed from the prior year.
  • Goodwill & Intangibles for Q2 2025 was $13.0 million at ARS Pharmaceuticals, up from $251000.0 in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $13.0 million in Q2 2025 and bottomed at $251000.0 in Q1 2025.